To the Editor In a recent cohort biomarker study, Tie and colleagues1 demonstrated the prognostic value of circulating tumor DNA (ctDNA) analysis after either surgery or adjuvant chemotherapy in stage III colon cancer. We agree with and value the identification of longitudinal noninvasive markers of recurrence risk in patients with cancer; however, we would like to highlight additional aspects that should not be neglected in the study.